Boston Scientific Inks Pact With Aspect For Depression, Alzheimer’s Tests
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will enhance its neurostimulation business and reap profits from future Aspect Medical SystemsBIS brain-monitoring technology for depression under a $25 mil. development deal announced May 23
You may also be interested in...
Financings In Brief
Response Genetics goes public: Cancer diagnostics developer goes public June 5, netting about $17.4 million from an initial stock offering of 3 million shares at $7 each. More than half of the proceeds will go to development of pharmacogenomic cancer tests for assessing the risk of disease recurrence after surgery and predicting patients' response to chemotherapy to help guide personalized medical treatment, the Los Angeles firm says. The company, which recorded 2006 sales of $6 million, also plans to expand its existing pharmacogenomic testing services outside the United States. Response Genetics' core technologies enable extraction and analysis of genetic information from stored tumor specimens. The company's stock trades on the NASDAQ exchange under the symbol "RGDX." The IPO was underwritten by Maxim Group and Caris & Company...
Financings In Brief
Response Genetics goes public: Cancer diagnostics developer goes public June 5, netting about $17.4 million from an initial stock offering of 3 million shares at $7 each. More than half of the proceeds will go to development of pharmacogenomic cancer tests for assessing the risk of disease recurrence after surgery and predicting patients' response to chemotherapy to help guide personalized medical treatment, the Los Angeles firm says. The company, which recorded 2006 sales of $6 million, also plans to expand its existing pharmacogenomic testing services outside the United States. Response Genetics' core technologies enable extraction and analysis of genetic information from stored tumor specimens. The company's stock trades on the NASDAQ exchange under the symbol "RGDX." The IPO was underwritten by Maxim Group and Caris & Company...
Boston Scientific Banks On ICDs To Spark Stock Growth; Index Slips In 2005
Boston Scientific is counting on Guidant shareholders preferring its takeover offer to J&J's to regain Wall Street enthusiasm in the face of diminishing competitive advantages for Taxus and a 31% stock decline in 2005